BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave Therapeutics’ assets
BioNTech has reached a research and option agreement with Biotheus for two antibody candidates. Biotheus announced the deal Wednesday. It will grant BioNTech exclusive worldwide